References
- Parker S L, Tong T, Bolden S, et al. Cancer statistics, 1996. CA 1996; 65: 5–27
- Souquet P J, Chauvin F, Boissel J P, et al. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 1993; 342: 19–21
- Grilli R, Oxman A D, Julian J A. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough. J Clin Oncol 1993; 11: 1866–1872
- Sorensen J B, Clerici M, Hansen H H. Single-agent chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 1988; 21: 89–102
- Bonomi P D, Finkelstein D M, Ruckdeschel J C, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602–1613
- Klastersky J, Sculier J P, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 1990; 8: 1556–1562
- Langer C J, Leighton J C, Comis R L, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860–1870
- Evans W K, Steward D J, Tomiak E, et al. Carboplatin and paclitaxel by one hour infusion for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 374
- Paul D, Devore R D, Hande K, et al. Phase II trial of carboplatin + paclitaxel in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 361
- Rowinsky E K, Sartorious S E, Bowling M K, et al. Paclitaxel on a 3-hour schedule and carboplatin in non-small-cell lung cancer: Use of maximally tolerated and clinically relevant single agent doses in combination is feasible. Proc Am Soc Clin Oncol 1995; 14: 354
- Vyberg M, Horn T, Francis D, et al. Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromo-granin and endocrine granule constituent in neuroendocrine tumours. Acta Histochem 1990; 38(Suppl)179–181
- Mitchell R B, Goss B, Guarino M, et al. Phase II trial of bisnafide in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 1230
- Chang A Y, Kim K, Blick J, et al. Phase II study of taxol, mer-barone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388–393
- Hainsworth J D, Thompson E S, Spigel S C, et al. Paclitaxel by 1-hour infusion in the treatment of stage IV or relapsed non-small-cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 364
- Ruckdeschel J, Wagner H, Williams C, et al. Second line chemotherapy for resistant, metastatic, non-small-cell lung cancer: The role of Taxol. Proc Am Soc Clin Oncol 1994; 13: 357
- Murphy W K, Winn R J, Huber M, et al. Phase II study of Taxol in patients with non-small-cell lung cancer who have failed platinum containing chemotherapy. Proc Am Soc Clin Oncol 1994; 13: 363
- Haas C D, Gallardo R L, Moore B, et al. Effective salvage chemotherapy for relapsed or refractory non-small-cell lung cancer with mitomycin-C + paclitaxel + metronidazole. Proc Am Soc Clin Oncol 1996; 15: 391
- Roa V, Conner A, Mitchell R B. Carboplatin and paclitaxel for chemotherapy-naive patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 404
- Calvert A H, Newell D R, Gumbrell L A, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–1756